<DOC>
	<DOCNO>NCT02265510</DOCNO>
	<brief_summary>This study INCB052793 give patient advanced malignancy conduct two phase ; Phase 1a ( Monotherapy ) Phase 1b ( Combination Therapy ) . Each study phase two part ; dose escalation ( Part 1 ) expansion ( Part 2 ) .</brief_summary>
	<brief_title>An Open-Label Study Novel JAK-inhibitor , INCB052793 , Given Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Phase 1a Aged 18 year old Histologically cytologically confirm solid tumor hematologic malignancy Life expectancy 12 week longer Must receive ≥ 1 prior treatment regimen Must candidate potentially curative standard care approve therapy Phase 1b Aged 18 year old Cohort A : Histologically cytologically confirm pancreatic adenocarcinoma , triplenegative breast cancer , urothelial cancer least 1 measurable evaluable target lesion Cohorts B , C , D , E G : Histologically confirm multiple myeloma measureable/evaluable disease Cohort F : Confirmed acute myeloid leukemia myelodysplastic syndrome Cohort H : Individuals diagnose lymphoma Prior therapy : Cohort A : No 1 prior chemotherapy regimen advance metastatic disease ( include neoadjuvant and/or adjuvant therapy ) Cohorts B , C , D , E G : Must relapse refractory ≥ 2 prior treatment regimen Cohort F : May receive number prior treatment regimen treatmentnaïve Cohort H : Must relapse refractory available treatment Prior receipt JAK1 inhibitor ( Phase 1a ) Known active central nervous system metastases and/or carcinomatous meningitis Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Any known contraindication use gemcitabine , nabpaclitaxel , dexamethasone , carfilzomib , bortezomib , lenalidomide , azacitidine , pomalidomide PI3Kδ inhibitor ( Phase 1b , appropriate treatment cohort ) Known human immunodeficiency virus infection , evidence hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection risk reactivation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>